BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Nov. 9, 2005
View Archived Issues
AstraZeneca: Q3 update
Read More
Introgen and Colgate-Palmolive form oral care alliance
Read More
Fovea completes Series A financing to develop drugs for retinal diseases
Read More
Emisphere receives FDA guidance on oral heparin phase III trial
Read More
OT-551 begins phase II trial in cataract prevention
Read More
Kos and Jerini sign agreement for icatibant in U.S. and Canada
Read More
Safety milestone in Osiris' stem cell trial for heart attack patients
Read More
Bionomics reviews operations
Read More
Mechanistic profile of Intermune's agents for IPF
Read More
Probenecid may halve the needed dose of oseltamivir
Read More
New tool to assess role of alpha1D- and alpha1B-ARs in prostate cancer
Read More
Hepcidin - a new target to prevent anemia of inflammation
Read More
Novel compounds with potential use in cardiovascular diseases reported
Read More
Not approvable letter for premature ejaculation drug dapoxetine
Read More
Recent patents disclose novel agents for dermatological disorders
Read More
Novel oligonucleotides for immunological disorders emerge from Coley R&D
Read More
Complement inhibition may reduce injury in coronary bypass surgery patients
Read More
Brivaracetam granted orphan drug status for symptomatic myoclonus
Read More
Meta-analyses reveal efficacy of gemifloxacin in resistant infections and high-risk patients
Read More
New data confirms the benefits of sitaxsentan in PAH
Read More
Update on the pharmacokinetics of alvimopan
Read More
A second phase III study confirms the therapeutic benefits of ranibizumab in AMD
Read More